華領醫藥-B(02552.HK)在CDS 2020上公佈多扎格列艾汀的進一步研究資料
格隆匯 11 月 26日丨華領醫藥-B(02552.HK)發佈公告，2020年11月26日，華領醫藥今天公佈了多扎格列艾汀(dorzagliatin)與二甲雙胍聯合用藥註冊臨牀研究DAWN(也稱HMM0302)的24周進一步分析資料。
在中華醫學會糖尿病學分會第二十四次全國學術會議(CDS 2020)上，華領醫藥將通過口頭報告和專題討論會對DAWN研究進行報告。24周研究資料顯示，針對二甲雙胍足量治療(1500mg╱天)失效的2型糖尿病患者，多扎格列艾汀治療組HbA1c較基線降低1.02%，比安慰劑對照組多下降0.66%(安慰劑組為0.36%)，p值<0.0001，藥效顯著，明顯優於二甲雙胍單藥治療。多扎格列艾汀還顯示出了以下特徵：快速起效，糖化血紅蛋白(HbA1c)在用藥4周後有效下降；與安慰劑對照組相比，治療組的β細胞功能顯著改善，胰島素抵抗降低；與安慰劑對照組相比，治療組的餐後2小時血糖值顯著下降；安全性和耐受性好，低血糖發生率低(24周治療期內低於1%)；超過24周持續有效?良好的應答率
“與二甲雙胍聯合用藥的分析資料進一步驗證了多扎格列艾汀“修復傳感，恢復血糖穩態”的科學理念，”華領醫藥首席執行官兼首席科學官陳力博士表示，“研究結果證明了多扎格列艾汀在二甲雙胍足量治療失效的2型糖尿病患者中的治療潛力，我們將繼續探索多扎格列艾汀作為2型糖尿病基石用藥，聯合市面上其它降糖藥的治療方案，更好地服務廣大患者。”
除此之外，多扎格列艾汀與SGLT-2抑制劑、與DPP-4抑制劑等主要治療藥物的聯合用藥臨牀研究結果均表明，聯合用藥具有明顯增效作用，能夠顯著提高血糖控制能力。
臨牀試驗中，多扎格列艾汀在血糖控制方面展現出了積極成效。對多扎格列艾汀與二甲雙胍聯合用藥的III期臨牀試驗分析表明，多扎格列艾汀在治療2型糖尿病方面顯示出了積極前景。
在本次CDS2020會議上，華領醫藥還將報告葡萄糖激酶啟動劑(GKA)的開發歷史、多扎格列艾汀與其它GKA的差異等，進一步闡述多扎格列艾汀作為葡萄糖增敏劑，修復葡萄糖激酶功能，恢復人體血糖敏感性，重塑血糖穩態，從而達到從根本上治療糖尿病的核心科學理念。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
